Source link : https://newshealth.biz/health-news/pola-r-gemox-boosts-survival-in-r-r-dlbcl/
MILAN — Combining polatuzumab vedotin (Pola) with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improves survival outcomes in patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to new data from the phase 3 POLARGO trial. Presented by Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, New Brunswick, […]
The post Pola-R-GemOx Boosts Survival in R/R DLBCL first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-15 16:37:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8